• Safety & Recalls
  • Regulatory Updates
  • Drug Coverage
  • COPD
  • Cardiovascular
  • Obstetrics-Gynecology & Women's Health
  • Ophthalmology
  • Clinical Pharmacology
  • Pediatrics
  • Urology
  • Pharmacy
  • Idiopathic Pulmonary Fibrosis
  • Diabetes and Endocrinology
  • Allergy, Immunology, and ENT
  • Musculoskeletal/Rheumatology
  • Respiratory
  • Psychiatry and Behavioral Health
  • Dermatology
  • Oncology

Generics Recently Launched in the United States

Article

Generic launches include equivalents of Combigan, Abraxane, Cytotec, Solu-Medrol, and Tobradex.

Sandoz Launches Second Generic of Combigan

Sandoz, a division of Novartis, has launched in the United States a generic of the combination eyedrop brimonidine tartrate/timolol maleate ophthalmic solution 0.2%/0.5%, a generic equivalent to AbbVie’s Combigan, to lower eye pressure in patients with ocular hypertension.

Apotex launched the first generic version of Combigan in January 2022.

Anyone can develop ocular hypertension, but certain groups are at higher risk, including African Americans and Hispanics, people over age 40, people living with diabetes or high blood pressure, and people who take long-term steroid medicines.

Additionally, Sandoz in February 2022 launched the generic lenalidomide in 19 countries in Europe. It is indicated for several hematology conditions.

Apotex Launches Generic of Abraxane

Apotex has launched the paclitaxel protein-bound particles for injection (albumin-bound), a generic version of Bristol Myers Squibb’s Abraxane in the United States. Paclitaxel protein-bound particles for injectable suspension is indicated for the treatment of metastatic breast cancer, non-small cell lung cancer and adenocarcinoma of the pancreas.

ANI Pharmaceutical Launches Generic Misoprostol Tablets

ANI Pharmaceuticals has launched of a generic of Pfizer’s Cytotec, which is indicated for reducing the risk of NSAID-induced gastric ulcers in patients at high risk of complications from gastric ulcers. ANI’s misoprostol tablets are available in 100 mcg and 200 mcg dosages.

ANI executives said in a press release this meets healthcare needs because of current shortages of misoprostol. One manufacturer, Lupin, has discontinued misoprostol, and Pfizer currently has a shortage because of manufacturing delays.

Dr. Reddy’s Launches Generic Methylprednisolone

Dr. Reddy’s Laboratories has launched methylprednisolone sodium succinate for injection, the

generic equivalent of Pfizer’s Solu-Medrol, which is a corticosteroid used to treat allergic conditions and flare-ups of multiple sclerosis. Dr. Reddy’s methylprednisolone is supplied in 40 mg/vial,125 mg/vial single-dose vials each carton containing 25 vials; 500 mg and 1 gm multi-dose vial each carton containing 1 vial.

Padagis Launches Generic of Tobradex

Padagis has launched a generic version of Novartis’ Tobradex (tobramycin ophthalmic solution), which is indicated for steroid-responsive inflammatory ocular conditions. The Padagis team has partnered with Rafarm to leverage their sterile manufacturing to deliver this to the market, Padagis executives said in a press release.

© 2024 MJH Life Sciences

All rights reserved.